{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:00:20Z","timestamp":1787065220143,"version":"build-2736575974"},"reference-count":78,"publisher":"Wiley","issue":"s2","license":[{"start":{"date-parts":[[2004,7,6]],"date-time":"2004-07-06T00:00:00Z","timestamp":1089072000000},"content-version":"vor","delay-in-days":5,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["HIV Medicine"],"published-print":{"date-parts":[[2004,7]]},"abstract":"<jats:p>There have been few major advances in paediatric HIV management over the last 2 years. Decisions about starting antiretroviral therapy can now be based on a recent large meta\u2010analysis of the predictive value of CD4 and HIV RNA viral load (VL) in nearly 4000 untreated children, which is discussed in these updated guidelines. Risk estimates for progression to AIDS and death using surrogate markers can now be broken down by age, allowing more accurate discussion with families. In addition, there is increasing recognition of the problems of long\u2010term adherence, drug resistance and cumulative toxicity in adults and children. The controversy over whether to treat asymptomatic infants continues. For older children more data on the efficacy of ritonavir boosted protease inhibitor (PI) regimens suggests that these may be the PI option of first choice. There is still no adult or paediatric trial evidence on which to base decisions about whether to start with PI\u2010 or non\u2010nucleoside reverse transcriptase inhbitor (NNRTI)\u2010 based regimens, but the PENPACT 1 trial, which is addressing this question, is ongoing. There are increasing moves to provide simpler antiretroviral therapy (ART) regimens, including once daily dosing, but these lag behind adult regimens because of the paucity of pharmacokinetic data. Resistance assays should now be performed in all HIV\u2010infected infants exposed to ART in pregnancy. Therapeutic drug monitoring may be very important in children because of high between\u2010 and within\u2010child variability in drug absorption and metabolism. A trial to evaluate this should start shortly in Europe (PENTA 14 trial). The value of resistance tests for choice of second\u2010line and subsequent choices of ART regimens remain unproven (the PERA trial will report late in 2004), but resistance assays are increasingly being used. The issue of when to switch therapy also remains unanswered and is being addressed within the PENPACT 1 trial. Regular formal assessment of adherence is now the standard of care, and routine monitoring in the clinic for lipodystrophy syndrome (LDS) and other ART toxicities is increasingly important. These guidelines will be updated again in 2006.<\/jats:p>","DOI":"10.1111\/j.1468-1293.2004.00227.x","type":"journal-article","created":{"date-parts":[[2004,7,6]],"date-time":"2004-07-06T06:36:08Z","timestamp":1089095768000},"page":"61-86","source":"Crossref","is-referenced-by-count":96,"title":["PENTA guidelines for the use of antiretroviral therapy, 2004"],"prefix":"10.1111","volume":"5","author":[{"given":"M","family":"Sharland","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Blanche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Castelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Ramos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"DM","family":"Gibb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the PENTA Steering Committee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2004,7,6]]},"reference":[{"key":"e_1_2_7_2_2","first-page":"230","article-title":"Five year follow up of vertically infected children in a randomised double blind controlled trial of immediate versus deferred zidovudine","volume":"84","author":"Paediatric European Network for Treatment of AIDS (PENTA).","year":"2001","journal-title":"the PENTA 1 trial"},{"key":"e_1_2_7_3_2","first-page":"756","article-title":"Disease progression in HIV infected infants and children","volume":"279","author":"Palumbo PE","year":"1998","journal-title":"predictive value of quantitative plasma HIV RNA and CD4 lymphocyte count"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1086\/516441"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)14793-9"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.327.7422.1019"},{"key":"e_1_2_7_7_2","unstructured":"FayeA.Mortality and morbidity in HIV\u2010infected infants treated before 6 months of age.II Conference of International AIDS Society Paris 2003 [Abstract 33]."},{"key":"e_1_2_7_8_2","unstructured":"RamosJT MansoB OteroMCet al. Early HAART in infants: a multicenter Spanish audit.9th European AIDS Conference (EACS) Warsaw 2003 [Abstract 15.2\/2]."},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1097\/00006454-200206000-00008"},{"key":"e_1_2_7_10_2","first-page":"237","article-title":"A 72 week follow\u2010up of HAART started in infants aged less than 3 months","volume":"18","author":"Pediatric European Network for treatment of AIDS.","year":"2004","journal-title":"CD4, viral load and drug resistance in the PENTA7 study"},{"key":"e_1_2_7_11_2","first-page":"6984","article-title":"Early therapy of vertical human immunodeficiency virus type\u20101 (HIV\u20101) infection","volume":"74","author":"Luzuriaga K","year":"2000","journal-title":"control of viral replication and absence of persistent HIV-1 specific immune responses"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1136\/adc.76.4.334"},{"key":"e_1_2_7_13_2","first-page":"19","article-title":"Prognosis of HIV\u20101 infected patients starting highly active antiretroviral therapy","volume":"360","author":"Egger M","year":"2002","journal-title":"a collaborative analysis of prospective studies"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200309050-00004"},{"key":"e_1_2_7_15_2","first-page":"679","article-title":"Prognostic importance of initial response in HIV\u2010infected patients starting potent antiretroviral therapy","volume":"362","author":"ATCC \u2013 The Antiviral Therapy Cohort Collaboration.","year":"2003","journal-title":"analysis of prospective studies"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1097\/00006454-200301000-00014"},{"key":"e_1_2_7_17_2","unstructured":"Tudor\u2010WilliamG HeadS WeigelRet al. Baby cocktail! A protease\u2010sparing 4 drug combination for symptomatic children.XIV International AIDS Conference Barcelona 2002 [Abstract MoOrB1129]."},{"key":"e_1_2_7_18_2","first-page":"492","article-title":"Nucleoside analogs plus ritonavir in stable antiretroviral therapy experienced HIV infected children","volume":"283","author":"Nachman SA","year":"2000","journal-title":"a randomized controlled trial. Pediatric AIDS Clinical Trials Group 338 Study Team"},{"key":"e_1_2_7_19_2","first-page":"1113","article-title":"Combination nucleoside analog reverse transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir in stable antiretroviral experienced HIV infected children","volume":"16","author":"Wiznia A","year":"2000","journal-title":"week 24 of a randomised controlled trial \u2013 PACTG 377"},{"key":"e_1_2_7_20_2","unstructured":"GibbDM GiaquintoC WalkerSet al. for the PENTA 5 Steering Committee. Three\u2010year follow\u2010up of the PENTA 5 Trial.10th Conference of Retrovirus and Opportunistic Infections Boston 2003 [Abstract 874]."},{"key":"e_1_2_7_21_2","first-page":"733","article-title":"Comparison of dual nucleoside analogue reverse\u2010transcriptase inhibitor regimens with and without NFV in children with HIV who have not previously been treated","volume":"359","author":"PENTA.","year":"2002","journal-title":"the PENTA 5 trial"},{"key":"e_1_2_7_22_2","unstructured":"GatellJ. Nelfinavir 625\u2003mg film\u2010coated tablets. Investigation of safety and gastrointestinal tolerability of this new formulation in comparison with 250\u2003mg film\u2010coated tablets in HIV patients.2nd International AIDS Society Conference Paris 2003 [Abstract 548]."},{"key":"e_1_2_7_23_2","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1097\/01.inf.0000055061.97567.34","article-title":"Forty\u2010eight\u2010week evaluation of lopinavir\/ritonavir, a new protease inhibitor, in human immunodeficiency virus infected children","volume":"22","author":"Saez\u2010Llorens X","year":"2003","journal-title":"Pediatr Infect Dis J"},{"key":"e_1_2_7_24_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199912163412501"},{"key":"e_1_2_7_25_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199912163412502"},{"key":"e_1_2_7_26_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa030264"},{"key":"e_1_2_7_27_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200307250-00008"},{"key":"e_1_2_7_28_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200101260-00014"},{"key":"e_1_2_7_29_2","unstructured":"Vibhagool A on behalf of the CNA3014 International Study Team. Ziagen (abacavir)\/combivir versus indinavir\/combivir in therapy na\u00efve adults.1st IAS Conference on HIV Pathogenesis and Treatment Buenos Aires Argentina 2001."},{"key":"e_1_2_7_30_2","first-page":"178","article-title":"Efficacy and safety of a quadruple combination combivir+abacavir+efavirenz regimen in antiretrovial treatment naive HIV\u20101 infected adults","volume":"31","author":"De Turchis P","year":"2002","journal-title":"La ranciliene"},{"key":"e_1_2_7_31_2","unstructured":"WellsCJ SharlandM SmithCJ. Triple nucleoside analogue therapy with zidovudine (AZT) lamivudine (3TC) and abacavir (ABC) in the paediatric HIV in South London (PHILS\u2010NET) cohort. A 72 week update.World Aids Conference Bangok 2004 [Abstract 2038]."},{"key":"e_1_2_7_32_2","unstructured":"BergshoeffA BurgerD FarrellyLet al. Pharmacokinetics of once daily vs. twice daily lamivudine and abacavir in HIV\u20101 infected children: PENTA 13.11th Conference on Retroviruses and Opportunistic Infections S. Francisco 2004 [Abstract 934]."},{"key":"e_1_2_7_33_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.1.183-191.2004"},{"key":"e_1_2_7_34_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.1.124-129.2004"},{"key":"e_1_2_7_35_2","unstructured":"HazraR GafnisR MaldarelliFet al. Safety tolerability and clinical responses to tenofovir DF in combination with other antiretrovirals in heavily treatment\u2010experienced HIV\u2010infected children: data through 48 weeks.11th Conference on Retroviruses and Opportunistic Infections S. Francisco 2004 [Abstract 928]."},{"key":"e_1_2_7_36_2","unstructured":"McKinneyR RathoreM JankelovichSet al. PACTG 1021: an ongoing phase I\/II study of once\u2010daily emtricabine didanosine and efavirenz in therapy\u2010naive or minimally treated pediatric patients.10\u00b0Conference of Retrovirus and Opportunistic Infections Boston 2003 [Abstract 873]."},{"key":"e_1_2_7_37_2","unstructured":"Saez\u2010LlorensX ViolariA NdiweniDet al. for FTC\u2010203 Study Team. Once\u2010daily emtricitabine in HIV\u2010infected pediatric patients with other antiretroviral agents.10th Conference of Retrovirus and Opportunistic Infection Boston 2003 [Abstract 872]."},{"key":"e_1_2_7_38_2","unstructured":"WilliamsI AsboeD BabikerAet al. A virological benefit from an induction\/maintenance strategy: The FORTE Trial.11th Conference on Retroviruses and Opportunistic Infections Chicago 2004 [Abstract 564]."},{"key":"e_1_2_7_39_2","first-page":"275","article-title":"Impact of protease inhibitor substitution with efavirenz in HIV\u2010infected children","volume":"3","author":"McComsey G","year":"2003","journal-title":"results of the first pediatric switch study"},{"key":"e_1_2_7_40_2","first-page":"446","article-title":"IMMUNOLOGIC CHANGES DURING UNPLANNED TREATMENT interruptions of highly active antiretroviral therapy in children with human immunodeficiency virus type 1 infection","volume":"63","author":"Gibb DM.","year":"2000","journal-title":"Pediatr Infect Dis J"},{"key":"e_1_2_7_41_2","first-page":"741","article-title":"Therapeutic drug monitoring","volume":"63","author":"Aarnoutse RE","year":"2003","journal-title":"an aid to optimising response to antiretroviral drugs?"},{"key":"e_1_2_7_42_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa035103"},{"key":"e_1_2_7_43_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200310170-00006"},{"key":"e_1_2_7_44_2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.109.4.e61"},{"key":"e_1_2_7_45_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-199909100-00021"},{"key":"e_1_2_7_46_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-133-1-200007040-00004"},{"key":"e_1_2_7_47_2","doi-asserted-by":"crossref","unstructured":"FarleyJ HinesS.MuskA.FerrusS.TapperV.Assessment of adherence to antiviral therapy in HIV\u2010infected children using the medication Event monitoring system pharmacy refill provider assessment Caregiver self\u2010report and appointment keeping. J Acquir Immune Defic Syndr2003;33:211\u2013218.","DOI":"10.1097\/00126334-200306010-00016"},{"key":"e_1_2_7_48_2","doi-asserted-by":"publisher","DOI":"10.1097\/00006454-199908000-00006"},{"key":"e_1_2_7_49_2","doi-asserted-by":"publisher","DOI":"10.1097\/00006454-200012000-00005"},{"key":"e_1_2_7_50_2","doi-asserted-by":"publisher","DOI":"10.1097\/00006454-200301000-00015"},{"key":"e_1_2_7_51_2","doi-asserted-by":"publisher","DOI":"10.1097\/00006454-200112000-00017"},{"key":"e_1_2_7_52_2","doi-asserted-by":"publisher","DOI":"10.1345\/aph.10201"},{"key":"e_1_2_7_53_2","first-page":"568","article-title":"Efficacy and toxicity of antiretroviral therapy using 4 or more agents","volume":"156","author":"Melvin AJ","year":"2002","journal-title":"application of a strategy for antiretroviral management in human immunodeficiency virus-infected children"},{"key":"e_1_2_7_54_2","doi-asserted-by":"publisher","DOI":"10.1097\/00006454-200301000-00018"},{"key":"e_1_2_7_55_2","doi-asserted-by":"publisher","DOI":"10.1097\/00006454-200205000-00011"},{"key":"e_1_2_7_56_2","unstructured":"RamosJT Garc\u00edaL RojoPet al. High prevalence of metabolic abnormalities in HIV\u2010infected children treated with HAART.10th Conference on Retrovirus and Opportunistic Infections Boston 2003 [Abstract 772]."},{"key":"e_1_2_7_57_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200009290-00008"},{"key":"e_1_2_7_58_2","unstructured":"ViganoA ThorneC. Fat redistribution and metabolic abnormalities in HIV\u2010infected children and adolescents in Europe.10th Conference on Retrovirus and Opportunistic Infections Boston 2003 [Abstract 774]."},{"key":"e_1_2_7_59_2","doi-asserted-by":"publisher","DOI":"10.1097\/00126334-200105010-00005"},{"key":"e_1_2_7_60_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200112070-00009"},{"key":"e_1_2_7_61_2","unstructured":"WatsonDC FarleyJJ. Hypercholesterolemia in children treated with HIV protease inhibitors.6th Conference on Retroviruses and Opportunistic Infections Chicago 1999 [Abstract 435]."},{"key":"e_1_2_7_62_2","first-page":"288","article-title":"Hyperlipidemia in HIV\u2010infected children treated with protease inhibitors","volume":"30","author":"Cheseaux JJ","year":"2002","journal-title":"relevance for cardiovascular diseases"},{"key":"e_1_2_7_63_2","first-page":"257","article-title":"Management of metabolic complications associated with antiretroviral therapy for HIV\u20101 infection","volume":"31","author":"Schambelan M","year":"2002","journal-title":"Recommendations of an International AIDS Society-USA Panel"},{"key":"e_1_2_7_64_2","first-page":"167","article-title":"Editorial response","volume":"31","author":"Brinkman K.","year":"2000","journal-title":"hyperlactatemia and hepatic steatosis as features of mitochondrial toxicity of nucleoside analogue reverse transcriptase inhibitors"},{"key":"e_1_2_7_65_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.inf.0000083826.11124.b1"},{"key":"e_1_2_7_66_2","doi-asserted-by":"publisher","DOI":"10.1067\/mpd.2001.112653"},{"key":"e_1_2_7_67_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.inf.0000086400.93257.74"},{"key":"e_1_2_7_68_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(99)07219-0"},{"key":"e_1_2_7_69_2","first-page":"1769","article-title":"Persistent mitochondrial dysfunction in HIV\u20101\u2010exposed but uninfected infants","volume":"17","author":"Barret B","year":"2003","journal-title":"clinical screening in a large prospective cohort"},{"key":"e_1_2_7_70_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-137-1-200207020-00008"},{"key":"e_1_2_7_71_2","first-page":"e74, 1","article-title":"Avascular necrosis of the hip (Leggs\u2010Calve\u2010Perthes disease) in HIV\u2010infected children in long\u2010term follow\u2010up","volume":"109","author":"Gaughan DM","year":"2002","journal-title":"PACTG Study 219"},{"key":"e_1_2_7_72_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200003100-00005"},{"key":"e_1_2_7_73_2","doi-asserted-by":"publisher","DOI":"10.1097\/00126334-200307010-00001"},{"key":"e_1_2_7_74_2","doi-asserted-by":"publisher","DOI":"10.1097\/00126334-200204150-00004"},{"key":"e_1_2_7_75_2","unstructured":"ViganoA ZamproniI GiacometV BianchiR FiginiC MoraS. Analysis of bone mineral content in antiretroviral\u2010naive and highly active antiretroviral treated HIV\u2010infected children.11th Conference on Retrovirus and Opportunistic Infections S. Francisco 2004 [Abstract 943]."},{"key":"e_1_2_7_76_2","unstructured":"SchwarzwaldH EllisKJ EvansDLet al. Effect of HAART on bone density in HIV\u2010infected children.10th Conference on Retrovirus and Opportunistic Infections Boston 2003 [Abstract 778]."},{"key":"e_1_2_7_77_2","unstructured":"OleskeJM GaughanDM MofensonLM SeageGR DanknerVM HughesMD. Bone disorders in HIV\u2010infected and \u2010exposed children.14th World AIDS Conference Barcelona 2002 [Abstract TuPpB 2053]."},{"key":"e_1_2_7_78_2","unstructured":"MondyK PowderlyWG ClaxtoSAet al. Alendronate vitamin D and calcium for the treatment of osteopenia\/osteoporosis associated with HIV infection.10th Conference on Retrovirus and Opportunistic Infections Boston 2003 [Abstract 134]."},{"key":"e_1_2_7_79_2","doi-asserted-by":"publisher","DOI":"10.1097\/00126334-200303010-00009"}],"container-title":["HIV Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1468-1293.2004.00227.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1468-1293.2004.00227.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T21:49:58Z","timestamp":1695764998000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1468-1293.2004.00227.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,7]]},"references-count":78,"journal-issue":{"issue":"s2","published-print":{"date-parts":[[2004,7]]}},"alternative-id":["10.1111\/j.1468-1293.2004.00227.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1468-1293.2004.00227.x","archive":["Portico"],"relation":{},"ISSN":["1464-2662","1468-1293"],"issn-type":[{"value":"1464-2662","type":"print"},{"value":"1468-1293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,7]]}}}